在罗马尼亚,Cefiderocol对多抗药性格拉姆阴性临床隔离物的体外活性
Anda Baicus1,2,3, Valentina Daniela Sisu1,2, Andreia Domnica Tatar1,2
1Emergency University Hospital, 050098 Bucharest, Romania.
Antibiotics (Basel, Switzerland)
|November 27, 2025
概括
塞菲德罗科尔对抗多药耐药格拉姆阴性细菌表现出有希望的活性,但耐药性正在出现. 对抗卡巴胺耐药性感染的有效治疗,监测赛菲德罗科尔的敏感性至关重要.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 在格拉姆阴性细菌中获得的碳烯耐药性在严重感染中构成重大威胁.
- 多药耐药 (MDR) 格拉姆阴性病原体需要新型治疗剂.
研究的目的:
- 来自罗马尼亚的MDR格兰氏阴性临床分离物对塞菲德罗科尔的体外活性进行评估.
- 评估各种格拉姆阴性物种 (包括肠杆菌和非发酵物种) 中的塞菲德罗科尔敏感性.
主要方法:
- 对89个连续的MDR格拉姆阴性分离物的回顾性研究 (2024年11月至2025年2月).
- 包括肠道细菌 (n=66) 和非发酵物 (n=23) 如P. aeruginosa,S. maltophilia和A. baumannii.
- 用于敏感性测试的磁盘扩散方法.
主要成果:
- 总体而言,对Enterobacterales和P. aeruginosa的 cefiderocol敏感性为52.8%,单独对Enterobacterales的敏感性为63.6%.
- 所有分离物的66.3%是易受磁盘扩散的影响.
- 仅生产NDM的K. pneumoniae是耐药的,而NDM/OXA-48联合生产者显示了65.3%的易感性. 所有的P. aeruginosa都是易受感染的. A. baumannii 的敏感度为68.8%.
结论:
- 塞菲德罗科尔显示出治疗MDR格兰氏阴性感染的潜力.
- 产生NDM分离体的出现需要对 cefiderocol 产生耐药性的细菌学监测.
- 严格的监测是必要的,以防止抗 cefiderocol 的快速传播.
相关概念视频
Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
